xRead - Olfactory Disorders (September 2023)

20426984, 2022, 4, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.22929, Wiley Online Library on [04/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

575

PATEL et al.

TABLE IX-18 (Continued) Study

Year LOE Study design

Study groups CRS (n = 122)

Clinical end point Conclusions

B-SIT

Significant

Levy

2016 3

Prospective,

et al 1456

improvement in B-SIT Greater in CRSwNP improvement in QOD-NS Greatest improvement Significant

multi-institutional cohort

Soler

2015

3

Prospective cohort

CRS (n = 121)

QOD-NS

et al 1250

in patients with worse CT scores at baseline

Nguyen

2015

3

Prospective

CRSwNP (n = 65)

VAS

Significant

et al 1457

improvement in VAS

Nguyen

2015

3

Prospective

CRSwNP (n = 69)

SS-TDI

Improvement in OF

et al 1458

2015

3

Prospective

CRS (n = 311)

B-SIT

No significant

DeConde et al 1459

improvement on B-SIT

Kim

2015

4

Cohort

CRS (n = 68)

VAS

No significant

et al 1460

improvement on VAS

CRSwNP (n = 17)

VAS UPSIT R

Kuperan et al 1461

2015

3

Randomized prospective

OC surgery improves

olfaction on UPSIT R

single-blinded

Hajjij

2015

4

Nested case-control

CRS (n = 40)

B-SIT

No significant

et al 1462

improvement in B-SIT

DeConde et al 149

B-SIT

Compared with

2014 3

Prospective cohort

CRS (N = 280) ESS (n = 222) Medical management (n = 58)

baseline, both groups improved No significant difference between groups

Jiang

2014 4

Case-control

CRSwNP (n = 52) CRSsNP (n = 48)

UPSIT R

No significant

et al 1463

improvement in UPSIT R improvement in SS andQOD

Katotomichelakis et al 1373

2014 3

Prospective

CRS (n = 116)

SS-TDI QOD-NS

Significant

Minwegen et al 1464

2014 3

Prospective

CRS (n = 38)

SS-ID (12 odor)

Significant

improvement in SS

Subjective symptom score (0–10)

Compared with

Baradaranfar et al 1465

2014 3

Nonrandomized clinical

CRS (n = 60) ESS followed by fluticasone Fluticasone

fluticasone alone, the ESS + fluticasone group showed significant improvement

Murthy

2013 3

Prospective

CRS (n = 71)

VAS

Significant

et al 1466

observational

improvement in VAS

Saedi

2013 3

Prospective

CRS (n = 89)

UPSIT R

Significant

et al 1467

improvement in UPSIT R

(Continues)